369 results on '"Nokihara H"'
Search Results
2. Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer)
3. Relation Between Baseline Asthma Treatment and COVID-19: Evaluating the Data in National Medical Center in Japan
4. MA08.08 Association of FDG-PET/CT Findings with Sufficient Amount of Tissue Samples for Gene Panel Testing in TBB/TBNA.
5. The examination of the second-line chemotherapy in SCLC patients with interstitial lung disease
6. A randomized, open-label, multicenter, phase 3 study to compare the efficacy and safety of eribulin to treatment of physician’s choice in patients with advanced non-small cell lung cancer
7. 1307P Real-world evaluation of first-line (1L) pembrolizumab (pembro) monotherapy for PD-L1–positive (TPS ≥50%), advanced NSCLC in Japan
8. 1292P Two single-arm, multicenter phase-II trials of PD-1 inhibitors in patients with pulmonary sarcomatoid carcinoma (NCCH1603/NCCH1703)
9. 1321P Real-world treatments and clinical outcomes in advanced NSCLC without actionable mutations after introduction of immunotherapy (IO) in Japan
10. Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4)
11. Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors
12. FEASIBILITY STUDY OF HIGH DOSE CISPLATIN ADMINISTERED WITH SHORT HYDRATION AND MAGNESIUM SUPPLEMENTATION IN PATIENTS WITH LUNG CANCER
13. A phase II study of cisplatin and docetaxel administered as three consecutive weekly infusions for advanced non-small-cell lung cancer in elderly patients
14. P1.01-32 A Multicenter, Open-Label, Phase II Trial of S-1 Plus Carboplatin in Advanced Non-Small Cell Lung Cancer Patients with Interstitial Lung Disease
15. P3.02-041 EGFR Amplification Mediates Resistance to TAS121, A Third-Generation EGFR-TKI, in EGFR T790M-Positive Non-Small Cell Lung Cancer
16. P2.07-011 Long Follow up from Phase I Study of Nivolumab and Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer
17. OA 05.03 Clinical Activity of ASP8273 in Asian Non-Small Cell Lung Cancer Patients with EGFR Activating and T790M Mutations
18. MA 16.04 Phase II Trial of S-1 Treatment as Palliative-Intent Chemotherapy for Previously Treated Advanced Thymic Carcinoma
19. EAST-LC: Randomized controlled phase III trial of S-1 versus docetaxel (DOC) in patients with non-small cell lung cancer (NSCLC) who had received a platinum-based treatment: Results from patient-reported outcomes (PROs)
20. Phase II trial of S-1 treatment as palliative-intent chemotherapy for previously treated advanced thymic carcinoma
21. Phase 2 study of lenvatinib in patients with RET fusion-positive adenocarcinoma of the lung
22. 430P Comparison of multimodality therapy in clinical stage IIIAN2 non-small cell lung cancer: consecutive analysis of surgery, radiotherapy, chemotherapy and their combination
23. Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study
24. First site of relapse can predict different clinical courses in recurrent stage IIIA non-small cell lung cancer after definitive chemoradiotherapy
25. EAST-LC: Randomized controlled phase III trial of S-1 versus docetaxel in patients with non-small-cell lung cancer who had received a platinum-based treatment
26. Phase 2 study of lenvatinib (LN) in patients (Pts) with RET fusion-positive adenocarcinoma of the lung
27. Analysis of circulating cell-free DNA in plasma shows a higher detection rate of EGFR mutations in patients with extrathoracic disease progression
28. 449P Distribution of erlotinib to brain, tumor lesion and normal tissue analyzed by matrix assisted laser desorption/ionization mass spectrometry imaging and liquid chromatography-tandem mass spectrometry
29. 447P Efficacy of platinum-doublet chemotherapy for patients with lung cancer with epidermal growth factor receptor (EGFR) activating mutation after the failure of EGFR-tyrosine kinase inhibitors (TKIs) treatment
30. 372PD Reduction in nephrotoxicities using short hydration in chemotherapy containing cisplatin: a consecutive analysis of 467 patients with thoracic malignancies
31. 467P Efficacy of cranial radiotherapy prior to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer patients with brain metastases
32. 420O - EAST-LC: Randomized controlled phase III trial of S-1 versus docetaxel (DOC) in patients with non-small cell lung cancer (NSCLC) who had received a platinum-based treatment: Results from patient-reported outcomes (PROs)
33. 463 Multiplex detection of 17 kinds of oncogenic fusion and aberrant transcripts in formalin-fixed, paraffin embedded tissues of lung adenocarcinoma by molecular counting
34. 521 Phase II studies of Nivolumab in patients with Advanced Squamous (SQ) or Non-Squamous (NSQ) Non-Small Cell Lung Cancer (NSCLC)
35. Efficacy and Safety of Eribulin Compared with Treatment of Physician’s Choice (TPC) in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC): Results from a Phase 3 Study
36. 9LBA Antitumor activity of ASP8273, an irreversible mutant selective EGFR-TKI, in NSCLC patients with tumors harboring EGFR activating mutations and T790M resistance mutation
37. 1625P - Phase II trial of S-1 treatment as palliative-intent chemotherapy for previously treated advanced thymic carcinoma
38. 1994 - Phase 2 study of lenvatinib in patients with RET fusion-positive adenocarcinoma of the lung
39. A Phase 1 Study of Veliparib (Abt-888) in Combination with Carboplatin/Paclitaxel in Japanese Subjects with Non-Small Cell Lung Cancer (Nsclc)
40. Evaluation of Safety, Tolerability, Pharmacokinetics and Efficacy of Dabrafenib, a Braf Inhibitor, in Japanese Patients with Braf V600 Mutation-Positive Advanced Solid Tumors: a Phase I Study
41. Phase I Study of Anti-Pd-1 Antibody Ono-4538 and Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer
42. Oral Hydration As a Post-Hydration Method for Cisplatin (Cddp) Administration in Patients with Lung Cancer: a Prospective Multicenter Trial
43. Impact of Kras Mutation on the Response and Prognosis of Patients with Stage III Non-Squamous Non-Small Cell Lung Cancer
44. Adjuvant Chemotherapy in Patients with Completely Resected Small Cell Lung Cancer: A Retrospective Analysis of 26 Consecutive Cases
45. Secondary Osteosarcoma Developing 10 Years after Chemoradiotherapy for Non-small-cell Lung Cancer
46. Phase III Study of Crizotinib vs. Chemotherapy in Advanced ALK+ NSCLC: Patient-Reported Symptoms and Quality of Life
47. A Phase I and Dose-Finding Study of Lenvatinib (E7080) in Japanese Patients with Advanced Solid Tumors
48. A Phase 1 Study of Cabozantinib in Japanese Patients with Advanced Solid Tumors: Anti-Tumor Activity in NSCLC and GIST
49. Crizotinib vs. Pemetrexed or Docetaxel in Advanced Alk+ Non-Small Cell Lung Cancer: Subgroup Analysis in Profile 1007
50. Phase I Study of LY2523355, an EG5 Inhibitor, in Japanese Patients with Advanced Solid Tumors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.